After decades of neglect, malnutrition-related diabetes, or type 5, is finally getting the research, recognition, and ...
Objective: Health care resource utilization (HCRU) and cost among Medicaid patients with serious mental illness (SMI) were ...
Mark Malesker, PharmD, discusses the clinical evidence, drug interaction risks, and formulary challenges surrounding cannabinoid use for sleep disorders.
Permanent rulemaking would replace IPAY 2026–2028 guidance, enabling predictable annual negotiations of up to 20 drugs and defined manufacturer agreement and renegotiation requirements. Formularies ...
AJMC: 64% of patients who responded to pCR skipped traditional chemotherapy entirely, and 97% avoided anthracyclines. For patients and oncologists, what does that mean in practice, and how do you ...
New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal. In this installment of this series, ‘The Future of Factor XIa ...
In this episode titled, 'Understanding Neuroendocrine Carcinomas: Definitions, Types, and Clinical Presentation,' Ryan Haumschil ...
Specialty pharmacies reduce administrative burden and total cost of care as advanced therapies move to community sites, Fran ...
Melanocyte melanin synthesis creates constitutive ROS vulnerability, and impaired Nrf2-mediated antioxidant responses enable ...
For Europe to remain an attractive site for phase 3 research, he argued, regulatory predictability is paramount. El-Galaly ...
State data reveal 2026 ACA marketplace enrollment losses are accelerating post open enrollment, as cancellations surge and ...
Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis. Harrison, the study’s lead investigator, explained that while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results